Lixte Biotechnology (NASDAQ: LIXT) Reports Promising Ovarian Cancer Trial Results

April 13, 2026

Key Developments Lixte Biotechnology Group, Inc. (NASDAQ: LIXT) announced encouraging outcomes from a clinical study conducted in collaboration with dostarlimab, highlighting new potential for patients diagnosed with ovarian cancer. This trial, showcased at the Annual Society of Gynecological Care Conference, paired Lixte’s investigational agent LB-100 with the immune checkpoint inhibitor dostarlimab. The combination demonstrated promising efficacy, offering fresh hope for a difficult-to-treat disease with few effective therapies currently available. Lixte…

Read More >>